Navigation Links
New strategy for inhibiting virus replication
Date:8/14/2009

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

The team led by Professor Dr. Ralf Bartenschlager, Director of the Department of Molecular Virology at the Hygiene Institute of Heidelberg University Hospital, has identified a protein in infected liver cells that is essential for hepatitis C virus replication. Inhibiting this protein is highly efficient in blocking virus replication. The study is to be published in the prestigious journal Public Library of Science Pathogens.

Viruses need cellular proteins for replication

More than 170 million people worldwide are affected by chronic hepatitis C. In up to 80 percent of infections, the virus can not be eliminated but persists in the infected individual. These chronically infected persons have a high risk of developing serious liver inflammation, liver cirrhosis and even a liver cell tumor.

Viruses contain only a minimum of genetic material and therefore need a host cell for replication. An essential cell factor required for hepatitis C virus replication is cyclophilin, which promotes the proper folding of proteins and the formation of large protein assemblies. Cyclophilin can be inhibited very efficiently by a drug used primarily in the context of organ transplantation the immunosuppressant cyclosporin. In search for better tolerated drugs to trea chronic hepatitis C, derivatives of cyclosporin were developed that no longer suppress the immune system, but still effectively inhibit cyclophilin. One of these derivatives is DEBIO-025. Although the exact antiviral mechanism by which DEBIO-025 inhibits hepatitis C virus replication is not yet known, clinical studies are already being conducted.

The critical protein is cyclophilin A'/>"/>

Contact: Dr. Ralf Bartenschlager
Ralf_Bartenschlager@med.uni-heidelberg.de
062-215-64569
University Hospital Heidelberg
Source:Eurekalert

Page: 1 2

Related biology news :

1. A combined tooth-venom arsenal revealed as key to Komodo dragons hunting strategy
2. New therapeutic strategy could target toxic protein in most patients with Huntingtons disease
3. Therapeutic hypothermia is promising strategy to minimize tissue damage
4. RNA research strategy for Europe takes shape
5. Hope for a rabies eradication strategy in Africa
6. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
7. GUMC researchers hone in on new strategy to treat common infection
8. Effects of anthropogenic sound on marine mammals -- a research strategy
9. Scientists uncover Ebola cell-invasion strategy
10. New study raises concerns about proposed mitigation strategy for marine bycatch
11. Novel therapeutic strategy for colon cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... Research and Markets  has announced the ... Market 2014-2018" report to their offering. ... term BI refers to applications and technologies that are ... about a company,s operations. BI help organizations to acquire ... example, metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... Swimming microorganisms, such as bacteria and spermatozoa, are subjected ... forces exerted by the surrounding fluid. Such low-level ... found that the direction of propulsion made possible by ... viscoelastic fluid. These findings have been published in ... Energies and Atomic Energy Commission (CEA), in Le Barp, ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
... to interact with the genes her unborn child inherits and ... research funded by the Wellcome Trust and the British Heart ... Molecular Genetics , suggests that mothers who eat a high ... the health of their offspring at risk. Congenital heart ...
... a new means of determining the sex of skeletal human ... the wake of disasters, the studying of ancient remains and ... able to determine the sex of skeletal remains by visually ... coxa. "This technique is accurate, but is not without its ...
... Ga. - Robots that revolutionized gynecologic and urologic surgery in ... least a portion of their diseased thyroid gland without the ... just under the Adam,s apple and controls the body,s metabolic ... cancerous disease can more than double its size. Dr. David ...
Cached Biology News:Maternal diet and genes interact to affect heart development 2Maternal diet and genes interact to affect heart development 3Hips don't lie: Researchers find more accurate technique to determine sex of skeletal remains 2Robots preclude neck incision for thyroid surgery 2
(Date:7/29/2014)... Rockville, MD (PRWEB) July 29, 2014 ... (ITI), a vaccine pioneer in the biotechnology industry, ... firm Newport Coast Securities, Inc. to explore financing ... commercializing LAMP-vax technology, a breakthrough vaccine platform with ... immunotherapy market. The company exclusively licensed the well-established ...
(Date:7/29/2014)... VONORE, Tenn. (PRWEB) July 29, 2014 ... leader in biomass feedstock supply innovation and supply ... new proprietary feedstock management systems, Energy Grangeā„¢ and ... years of R&D and in-the-field testing aimed at ... and offering benefits to landowners, farmers and feedstock ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 DisasterTalk is a ... people where cell phone masts or other transmitters are down. ... 100 feet away without the need for any Wi-Fi, and ... ranges. , The new app has launched as a ... are at very high risk of being affected by natural ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... Pharmaceutical and ... Biotech Industries, ... short-term and long-term biomaterials storage, sample,management and cold chain logistics, ... inaugural,Biorepositories 2008, the only U.S.-based event for the pharmaceutical and,biotech ...
... portfolio, CORAL GABLES, Fla., June 23 ... pharmaceutical company specializing in,dermatology, today announced it ... which Stiefel Laboratories will acquire Barrier Therapeutics,Inc. ... a two-step,transaction, a tender offer followed by ...
... JOLLA, Calif., June 23 TorreyPines Therapeutics,Inc. (Nasdaq: ... Kurtz, President and,Chief Executive Officer, will present data ... safety, tolerability and efficacy of three doses,of tezampanel ... the,50th Annual Scientific Meeting of the American Headache ...
Cached Biology Technology:BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2Barrier Therapeutics to Merge Into Stiefel Laboratories 2Barrier Therapeutics to Merge Into Stiefel Laboratories 3Barrier Therapeutics to Merge Into Stiefel Laboratories 4Barrier Therapeutics to Merge Into Stiefel Laboratories 5TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society 2
Request Info...
... Power Supply, 1. 3500 V, 400 mA, ... power, and linear voltage ramp modes.Linear voltage ... in IPG strips quickly without danger of ... in gel thickness, sample ionic strength, and ...
MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Biology Products: